Tag: pharmacogenomics market growth.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What is the Anticipated CAGR of the Pharmacogenomics Market, and What Factors Will Drive It?

There has been a swift expansion in the pharmacogenomics market size in the latter years. The expectation is for an upturn from $8.94 billion in 2024 to $9.84 billion in 2025, showing a compound annual growth rate (CAGR) of 10.0%. The notable growth during the historic span is due to the robust economic development in burgeoning markets, a heightened emphasis on bespoke medicine, the escalation in advanced healthcare structures, and elevated healthcare spending.

Expectations are high for a swift surge in the pharmacogenomics market in the coming years, with forecasts predicting the size to escalate to $14.53 billion by 2029, marking a compound annual growth rate (CAGR) of 10.2%. This projected increase during the forecast period is largely linked to an aging population, the prevalence of chronic diseases, population growth, and the heightened demand for cancer treatments. Key trends to watch for during this period include the introduction of genome editing solutions for advanced therapy analysis, the incorporation of artificial intelligence (AI) into genomics for enhanced genetic data examination, progress in metagenomics, strategic alliances and collaborations within the market, the utilization of three-dimensional (3D) genomics to investigate gene expression and function influences, novel product innovations targeting infectious diseases and gene editing, and the creation of psychotropic pharmacogenomics tests for insightful decision-making.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7072&type=smp

What Are the Core Growth Drivers Propelling the Pharmacogenomics Market Forward?

The pharmacogenomics market is experiencing increasing demand, largely fueled by the growing need for precision medicine. This medical model is focused on providing tailored healthcare, meaning that treatments, practices, and products are specifically adapted to the needs of individual patients, rather than a generic one-size-fits-all approach. Oncology is currently the field making the most use of precision medicine, but its potential reaches far beyond; it can also be applied to late-stage diseases, including rare and genetic diseases. The intent of precision medicine is to use information about specific diseases and their reactions to particular treatments in a more personalized, effective way. A March 2022 article on Linchpinseo suggested a 1/3 increase in precision medicine investment from major pharmaceutical companies over the next five years. In addition, there are 30 million individuals diagnosed and treated for type 2 diabetes in the USA, for whom precision medicine could greatly enhance treatment practices. Therefore, the surging demand for precision medicine is expected to positively impact the pharmacogenomics market.

What Segment Types Define the Pharmacogenomics Market Structure?

The pharmacogenomicsmarket covered in this report is segmented –

1) By Technology: Next Generation Sequencing, Polymerase Chain Reaction, Gel Electrophoresis, Mass Spectrometry, Microarray, Other Technologies

2) By Application: Neurological Diseases, Infectious Diseases, Oncology, Cardiovascular Diseases, Pain Management, Other Applications

3) By End User: Hospitals and Clinics, Research Institutions, Academic Institutes, Other End Users

Subsegments:

1) By Next Generation Sequencing (NGS): Whole Genome Sequencing, Targeted Sequencing, Exome Sequencing

2) By Polymerase Chain Reaction (PCR): Quantitative PCR (qPCR), Reverse Transcription PCR (RT-PCR), Digital PCR

3) By Gel Electrophoresis: Agarose Gel Electrophoresis, Polyacrylamide Gel Electrophoresis, Capillary Gel Electrophoresis

4) By Mass Spectrometry: LC-MS/MS (Liquid Chromatography-Tandem Mass Spectrometry), MALDI-TOF MS (Matrix-Assisted Laser Desorption/Ionization Time of Flight), HRMS (High-Resolution Mass Spectrometry)

5) By Microarray: SNP Microarrays, Expression Microarrays, Comparative Genomic Hybridization (CGH) Arrays

6) By Other Technologies: Sanger Sequencing, CRISPR-Based Technologies, Bioinformatics Tools

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=7072&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Pharmacogenomics Market?

North America was the largest region in the pharmacogenomics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmacogenomics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which Emerging Trends that Are Influencing thePharmacogenomics Industry Evolution?

The rise in technological innovation is a major trend gaining traction in the pharmacogenomics industry. Pharmaceutical manufacturers are honing various strategies for pharmacogenomics analysis in order to deliver cost-effective screening solutions for identified polymorphisms and the identification of new variants. To illustrate, Invitae, a medical laboratory based in the US, unveiled its improved Pharmacogenomics Panel in May 2022. The expanded Invitae Pharmacogenomics (PGx) Panel, which includes the Mental Health Panel, offers insights into how genes interact with medicine in different specialties such as primary care, cardiology, and oncology. Considering that around 25% of patients experience unique drug responses due to genetic factors, the use of PGx testing is poised to become a common practice. However, effective incorporation into healthcare mandates increased support for providers to comprehend and utilize PGx testing in their clinical environments.

View the full report here:

https://www.thebusinessresearchcompany.com/report/pharmacogenomics-global-market-report

What Is the Definition of the Pharmacogenomics Market?

Pharmacogenomics is a field of research that studies how a patient’s genes affect and how they respond to medications. The long-term aim of pharmacogenomics is to help doctors select the drugs and doses best suited for each person. Pharmacogenomics is used to create customized drugs to treat a variety of health issues, including cardiovascular disease, Alzheimer’s disease, cancer, and asthma. The pharmacogenomics marker refers to precise medical treatment for each person or a group of people.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=7072

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Pharmacogenomics Market?

The market size of pharmacogenomics has seen a quick expansion in the past years. The growth is projected to increase from $8.94 billion in 2024 to $9.92 billion in 2025, having a compound annual growth rate (CAGR) of 10.9%. The previous development has been propelled by robust economic advancements in developing markets, a heightened emphasis on tailor-made medication, improvement in sophisticated healthcare infrastructure and a rise in healthcare spending.

What Growth Rate Is Forecasted for the Pharmacogenomics Market by 2029?

In the coming years, the pharmacogenomics market is projected to experience swift expansion and is predicted to reach a value of $14.81 billion by 2029, growing at a compound annual growth rate (CAGR) of 10.5%. The significant growth during the forecast period can be attributed to factors such as an increasing elderly population, rising chronic illnesses, population growth and greater demand for cancer treatments. Key trends projected for the forecast period encompass the launch of genome editing solutions for more in-depth analysis of sophisticated therapies, a focus on integrating artificial intelligence (AI) in genomics for genetic data analysis, and continued advancements in metagenomics. Other factors include strategic alliances and cooperation between market participants, the introduction of 3D genomics for studying the impacts on gene expression and function, novel product innovations with an emphasis on infectious diseases and gene editing, as well as the development of psychotropic pharmacogenomics tests to aid informed decisions.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7072&type=smp

Which Key Companies Are Shaping the Future of the Pharmacogenomics Market?

Major companies operating in the pharmacogenomics market include Illumina Inc, Eurofins Scientific, Myriad Genetics Inc, PerkinElmer Inc, Centogene N.V, Invitae Corporation, Genomind, Pacific Biosciences of California Inc, Oneome LLC, Admera Health, MapMyGenome, Positive Bioscience, Xcode Life Sciences, Xcelris Labs, Takeda Pharmaceutical Company Limited, Garvan Institute of Medical Research, 3D Medicines Inc, Berry Genomics, BGI, GenomiCare Biotechnology, Bayer AG, GlaxoSmithKline plc (GSK), F Hoffmann-La Roche AG, Merck KGaA, QIAGEN N.V, Centro de Genoma e Biologia de Sistemas (CGBS), Dasa Group, Datar Cancer Genetics Limited, MedGenome Labs, 23andMe, Color Genomics, Pathway Genomics, Laboratório Richet, Laboratório Exame, Genomika Diagnósticos

Which Factors Are Driving Demand in the Pharmacogenomics Industry?

The escalating need for personalized medicine is fueling the pharmacogenomics market’s growth rate. This healthcare approach revolves around customized medical treatments, practices, decisions, or products, focusing on a specific group of patients rather than an all-encompassing drug-for-all model. The demand for such individualized medication has seen a rise, especially in oncology, with broader and more promising roles beyond merely cancer and late-stage ailments like unique and genetic disorders. The central objective of precision medicine is to amalgamate genetic and environmental specifics related to particular diseases or their responses to certain remedies. For instance, a Linchpinseo article from March 2022 states that big pharmaceutical companies’ investment in precision medicine is expected to rise by one-third over the next five years. Additionally, precision medication, with its tailor-made treatment, is coming to the aid of 30 million individuals suffering from type 2 diabetes in the USA, which will overhaul conventional treatment protocols. As a result, the burgeoning need for precision medicine is set to catalyze the pharmacogenomics market’s expansion.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=7072&type=smp

How Is the Pharmacogenomics Market Segmented by Several Divisions?

The pharmacogenomics market covered in this report is segmented –

1) By Technology: Next Generation Sequencing, Polymerase Chain Reaction, Gel Electrophoresis, Mass Spectrometry, Microarray, Other Technologies

2) By Application: Neurological Diseases, Infectious Diseases, Oncology, Cardiovascular Diseases, Pain Management, Other Applications

3) By End User: Hospitals and Clinics, Research Institutions, Academic Institutes, Other End Users

Subsegments:

1) By Next Generation Sequencing (NGS): Whole Genome Sequencing, Targeted Sequencing, Exome Sequencing

2) By Polymerase Chain Reaction (PCR): Quantitative PCR (qPCR), Reverse Transcription PCR (RT-PCR), Digital PCR

3) By Gel Electrophoresis: Agarose Gel Electrophoresis, Polyacrylamide Gel Electrophoresis, Capillary Gel Electrophoresis

4) By Mass Spectrometry: LC-MS/MS (Liquid Chromatography-Tandem Mass Spectrometry), MALDI-TOF MS (Matrix-Assisted Laser Desorption/Ionization Time of Flight), HRMS (High-Resolution Mass Spectrometry)

5) By Microarray: SNP Microarrays, Expression Microarrays, Comparative Genomic Hybridization (CGH) Arrays

6) By Other Technologies: Sanger Sequencing, CRISPR-Based Technologies, Bioinformatics Tools

What are the Emerging Market Trends Driving the Growth of the Pharmacogenomics Industry?

A key trend emerging in the pharmacogenomics market is the advancement of technology. Pharmaceutical manufacturers are concentrating on different methods of pharmacogenomics analysis in order to offer affordable options for screening identified polymorphisms and identifying new variations. In May 2022, for example, Invitae, a medical laboratory organization based in the United States, introduced its broader Pharmacogenomics Panel. The Invitae Pharmacogenomics (PGx) Panel, which includes the Mental Health Panel, provides information on how genetics affect medication responses across several specialties such as primary care, cardiology, and oncology. Given that nearly 25% of patients exhibit unusual drug reactions due to their genetic makeup, PGx testing is poised to become a routine procedure. However, a comprehensive integration into healthcare necessitates improved provider support for comprehending and implementing PGx testing in their clinical contexts.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/pharmacogenomics-global-market-report

Which Regions Are Driving Growth in the Pharmacogenomics Market?

North America was the largest region in the pharmacogenomics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmacogenomics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=7072

This Report Delivers Insight On:

1. How big is the pharmacogenomics market, and how is it changing globally?

2. Who are the major companies in the pharmacogenomics market, and how are they performing?

3. What are the key opportunities and risks in the pharmacogenomics market right now?

4. Which products or customer segments are growing the most in the pharmacogenomics market?

5. What factors are helping or slowing down the growth of the pharmacogenomics market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the pharmacogenomics industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

How Fast Is The Pharmacogenomics Market Expected to Grow Between 2025 And 2029?

In the previous years, the size of the pharmacogenomics market has witnessed rapid expansion. It is projected that from its 2024 estimate of $8.94 billion, it will surge to $9.92 billion in 2025, with a compound annual growth rate (CAGR) of 10.9%. Factors such as pronounced economic development in burgeoning markets, a heightened emphasis on bespoke medicine, surging superior healthcare infrastructures, and amplified healthcare spending have contributed to this historic period growth.

Rapid expansion is anticipated in the pharmacogenomics market in the coming years, with projections putting it at $14.81 billion in 2029 and a compound annual growth rate (CAGR) of 10.5%. Factors fueling this growth during the forecasted period includes an uptick in the aging population, the surge of chronic diseases, a rising global population, and a growing demand for cancer treatments. Noteworthy trends during this period include the introduction of genome editing solutions for deeper scrutiny of advanced therapies, an increased concentration on integrating artificial intelligence in genomics for genetic data analysis, further advancements in metagenomics, strategic collaboration and partnerships among market participants, the incorporation of three-dimensional (3D) genomics to assess the effects on gene expression and functionality, the innovation of new products focused on infectious diseases and gene editing, and the creation of psychotropic pharmacogenomics tests for more informed decision-making.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7072&type=smp

Which Major Market Drivers Are Expected to Boost the Growth Potential of the Pharmacogenomics Market?

The pharmacogenomics market is experiencing boosted demand due to the growing interest in precision medicine. This healthcare paradigm emphasizes personalized care, advocating medical procedures, treatments, or products designed for specific patient subsets, as opposed to a one-size-fits-all approach. The appeal of precision medicine is primarily seen in oncology but its impressive applications extend to other areas like late-stage, rare, and genetic diseases. Precision medicine’s goal is to consider genetic and environmental information relevant to specific diseases and their treatment responses. For instance, an article on Linchpinseo in March 2022 pointed out that major pharmaceutical companies’ investments in precision medicine would witness a one-third surge in five years. Furthermore, precision medicine is revolutionizing the treatment approach for the 30 million people diagnosed with type 2 diabetes in the US by offering personalized treatment strategies. Thus, the burgeoning demand for precision medicine is set to stimulate the pharmacogenomics market.

Which Key Market Segments Comprise the Pharmacogenomics Market and Drive Its Revenue Growth?

The pharmacogenomics market covered in this report is segmented –

1) By Technology: Next Generation Sequencing, Polymerase Chain Reaction, Gel Electrophoresis, Mass Spectrometry, Microarray, Other Technologies

2) By Application: Neurological Diseases, Infectious Diseases, Oncology, Cardiovascular Diseases, Pain Management, Other Applications

3) By End User: Hospitals and Clinics, Research Institutions, Academic Institutes, Other End Users

Subsegments:

1) By Next Generation Sequencing (NGS): Whole Genome Sequencing, Targeted Sequencing, Exome Sequencing

2) By Polymerase Chain Reaction (PCR): Quantitative PCR (qPCR), Reverse Transcription PCR (RT-PCR), Digital PCR

3) By Gel Electrophoresis: Agarose Gel Electrophoresis, Polyacrylamide Gel Electrophoresis, Capillary Gel Electrophoresis

4) By Mass Spectrometry: LC-MS/MS (Liquid Chromatography-Tandem Mass Spectrometry), MALDI-TOF MS (Matrix-Assisted Laser Desorption/Ionization Time of Flight), HRMS (High-Resolution Mass Spectrometry)

5) By Microarray: SNP Microarrays, Expression Microarrays, Comparative Genomic Hybridization (CGH) Arrays

6) By Other Technologies: Sanger Sequencing, CRISPR-Based Technologies, Bioinformatics Tools

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=7072&type=smp

Which Areas Are Leading Regions in the Pharmacogenomics Market Expansion Across the Globe?

North America was the largest region in the pharmacogenomics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmacogenomics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Key Market Trends in thePharmacogenomics Market Over the Coming Years?

A crucial trend gaining traction in the pharmacogenomics market is technological innovation. Drug manufacturers are honing multiple strategies for pharmacogenomics examination to offer cost-efficient solutions for screening recognized polymorphisms and uncovering new variants. For instance, in May 2022, Invitae, a medical laboratory company based in the US, introduced its extended Pharmacogenomics Panel. This expanded Invitae Pharmacogenomics (PGx) Panel, which encompasses the Mental Health Panel, affords an understanding of the genetic reactions to medicines across numerous specializations like general practice, cardiology, and oncology. PGx testing is predicted to become a standard procedure since approximately 25% of patients experience abnormal drug reactions due to genetics. A successful incorporation into healthcare necessitates heightened assistance for providers to grasp and incorporate PGx testing into their medical environments.

View the full report here:

https://www.thebusinessresearchcompany.com/report/pharmacogenomics-global-market-report

How Is the Pharmacogenomics Market Conceptually Defined?

Pharmacogenomics is a field of research that studies how a patient’s genes affect and how they respond to medications. The long-term aim of pharmacogenomics is to help doctors select the drugs and doses best suited for each person. Pharmacogenomics is used to create customized drugs to treat a variety of health issues, including cardiovascular disease, Alzheimer’s disease, cancer, and asthma. The pharmacogenomics marker refers to precise medical treatment for each person or a group of people.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=7072

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Factors Are Propelling the Market Growth of thePharmacogenomics Market from 2025 to 2034?

The escalating need for precision medicine is a driving factor for the growth of the pharmacogenomics market. Precision medicine involves personalized healthcare, where medical decisions, treatments, procedures, and products are made to fit certain patient groups rather than a generic one-drug-for-all approach. The increased need for precision medicine is evident since it is highly developed in the field of oncology and has wider, promising opportunities beyond oncology and late-stage diseases like rare and genetic disorders. The primary goal of precision medicine is to incorporate genetic and environmental details about specific illnesses and/or their reactions to certain treatments. For instance, an article on Linchpinseo in March 2022 reported that the growing demand for investments in precision medicine from major pharmaceutical companies is expected to see a rise of 1/3 over the next five years. Moreover, in the USA, precision medicine offers personalized treatments for the 30 million people diagnosed and treated for type 2 diabetes and aims to revolutionize current treatment approaches. As such, the pharmacogenomics market is set to grow due to the escalating demand for precision medicine.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7072&type=smp

#What Are the Key Projections for the CAGR of the Pharmacogenomics Market From 2025 to 2034?

The size of the pharmacogenomics market has experienced quick expansion in the past few years. It is projected to expand from $8.94 billion in 2024 to $9.92 billion in 2025, indicating a compound annual growth rate (CAGR) of 10.9%. The notable growth during the historical period can be linked to robust economic development in emergent markets, a heightened focus on personalized medicine, improvement in advanced healthcare facilities, and a rise in healthcare spending.

The size of the pharmacogenomics market is predicted to experience considerable growth in the impending years, reaching a value of $14.81 billion by 2029, boasting a compound annual growth rate (CAGR) of 10.5%. Factors contributing to this growth within the forecasted period include an incline in the aging populace, rising rates of chronic diseases, population growth, and a higher demand for cancer treatments. Key trends expected within the forecast period include the development of genome editing solutions for in-depth analysis of advanced therapies, the employment of artificial intelligence (AI) in genomics for genetic data analysis, improvements in metagenomics, strategic alliances and collaborations within market players, the advent of three-dimensional (3D) genomics to research influences on gene expression and functionality, the introduction of innovative products centered around infectious diseases and gene editing, and the creation of psychotropic pharmacogenomics tests for informed decisions.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=7072

How Are Market Trends and Innovations Revolutionizing thePharmacogenomics Industry in Recent Times?

The rise in technological progress is a notable trend that is gaining traction in the pharmacogenomics market. Companies manufacturing medications are concentrating on a variety of methods for pharmacogenomics study, aiming to offer cost-effective options for screening familiar polymorphisms and discovering new variations. For example, in May 2022, Invitae, a medical laboratory firm based in the USA, introduced its more extensive Pharmacogenomics Panel. The Invitae Pharmacogenomics (PGx) Panel, which includes the Mental Health Panel, offers knowledge into genetic responses to drugs in numerous areas such as primary care, cardiology, and oncology. PGx testing is set to become a norm as nearly 25% of patients experience unconventional drug responses due to their genetics. For a successful integration into healthcare, there is an urgent need for improved provider support to comprehend and implement PGx testing in various clinical situations.

Which Key Market Players Are Shaping the Future and Growth of thePharmacogenomics Market?

Major companies operating in the pharmacogenomics market include Illumina Inc, Eurofins Scientific, Myriad Genetics Inc, PerkinElmer Inc, Centogene N.V, Invitae Corporation, Genomind, Pacific Biosciences of California Inc, Oneome LLC, Admera Health, MapMyGenome, Positive Bioscience, Xcode Life Sciences, Xcelris Labs, Takeda Pharmaceutical Company Limited, Garvan Institute of Medical Research, 3D Medicines Inc, Berry Genomics, BGI, GenomiCare Biotechnology, Bayer AG, GlaxoSmithKline plc (GSK), F Hoffmann-La Roche AG, Merck KGaA, QIAGEN N.V, Centro de Genoma e Biologia de Sistemas (CGBS), Dasa Group, Datar Cancer Genetics Limited, MedGenome Labs, 23andMe, Color Genomics, Pathway Genomics, Laboratório Richet, Laboratório Exame, Genomika Diagnósticos

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/pharmacogenomics-global-market-report

What Are the Core Segments of the Pharmacogenomics Market, and How Do They Contribute to Growth?

The pharmacogenomics market covered in this report is segmented –

1) By Technology: Next Generation Sequencing, Polymerase Chain Reaction, Gel Electrophoresis, Mass Spectrometry, Microarray, Other Technologies

2) By Application: Neurological Diseases, Infectious Diseases, Oncology, Cardiovascular Diseases, Pain Management, Other Applications

3) By End User: Hospitals and Clinics, Research Institutions, Academic Institutes, Other End Users

Subsegments:

1) By Next Generation Sequencing (NGS): Whole Genome Sequencing, Targeted Sequencing, Exome Sequencing

2) By Polymerase Chain Reaction (PCR): Quantitative PCR (qPCR), Reverse Transcription PCR (RT-PCR), Digital PCR

3) By Gel Electrophoresis: Agarose Gel Electrophoresis, Polyacrylamide Gel Electrophoresis, Capillary Gel Electrophoresis

4) By Mass Spectrometry: LC-MS/MS (Liquid Chromatography-Tandem Mass Spectrometry), MALDI-TOF MS (Matrix-Assisted Laser Desorption/Ionization Time of Flight), HRMS (High-Resolution Mass Spectrometry)

5) By Microarray: SNP Microarrays, Expression Microarrays, Comparative Genomic Hybridization (CGH) Arrays

6) By Other Technologies: Sanger Sequencing, CRISPR-Based Technologies, Bioinformatics Tools

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=7072&type=smp

What Regions Are Dominating the Pharmacogenomics Market Growth?

North America was the largest region in the pharmacogenomics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmacogenomics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Pharmacogenomics Market 2025, By The Business Research Company:

Department Stores And Other General Merchandise Stores Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/department-stores-other-general-merchandise-stores-global-market-report

Other Health and Personal Care Stores Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/other-health-and-personal-care-stores-global-market-report

Pharmacies and Drug Stores Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/pharmacies-and-drug-stores-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What key factors are powering the surge in the pharmacogenomics market right now?

In recent years, there has been considerable expansion in the size of the pharmacogenomics market. The market, which was valued at $8.94 billion in 2024, is estimated to surge to $9.92 billion in 2025, with a compound annual growth rate (CAGR) of 10.9%. Factors such as robust economic development in emerging markets, a heightened emphasis on personalized medicine, evolving advanced healthcare infrastructure, and greater investments in healthcare could be credited for this surge over the historic period.

How fast Is the pharmacogenomics market expected to grow, and what’s its future value?

The market for mental wellness is predicted to experience substantial expansion in the upcoming years, anticipated to reach a size of $262.65 billion by 2029, rising at a compound annual growth rate (CAGR) of 8.9%. This projected growth during the forecasting period can be credited to factors such as the growing use of wearable devices, worldwide advocacy for mental health, emphasis on preventive mental health measures, virtual reality therapies, and custom mental wellness solutions. The future trends expected to shape this market include digital platforms for mental health, mental health initiatives within the corporate sector, incorporation of artificial intelligence (AI), and an overall focus on holistic wellness ecosystems that promote cultural diversity and inclusivity.

Get your pharmacogenomics market report here!

https://www.thebusinessresearchcompany.com/report/pharmacogenomics-global-market-report

What are the leading drivers of growth in the pharmacogenomics market?

The pharmacogenomics market is experiencing a surge in demand due to the compelling need for precision medicine. This healthcare model suggests a customized approach, wherein individual patients are treated with specific medical treatments, practices, or products, as opposed to utilizing a universal drug approach. Precision medicine, particularly ground-breaking within the realm of oncology, has promising applications extending even beyond oncology and into fields such as genetic and rare diseases. Precision medicine’s primary goal is to incorporate specific genetic and environmental information about diseases or their response to certain treatments. According to a Linchpinseo article in March 2022, the enhanced demand for precision medicine investments from top pharmaceutical firms is anticipated to rise by one third in the next five years. Additionally, in the USA, precision medicine’s capability to provide personalized treatment protocols has impacted the diagnosis and treatment of 30 million type 2 diabetes patients. Hence, the growth of the precision medicine sector will undeniably propel the pharmacogenomics market.

What are the key segments defining the pharmacogenomics market?

The pharmacogenomics market covered in this report is segmented –

1) By Technology: Next Generation Sequencing, Polymerase Chain Reaction, Gel Electrophoresis, Mass Spectrometry, Microarray, Other Technologies

2) By Application: Neurological Diseases, Infectious Diseases, Oncology, Cardiovascular Diseases, Pain Management, Other Applications

3) By End User: Hospitals and Clinics, Research Institutions, Academic Institutes, Other End Users

Subsegments:

1) By Next Generation Sequencing (NGS): Whole Genome Sequencing, Targeted Sequencing, Exome Sequencing

2) By Polymerase Chain Reaction (PCR): Quantitative PCR (qPCR), Reverse Transcription PCR (RT-PCR), Digital PCR

3) By Gel Electrophoresis: Agarose Gel Electrophoresis, Polyacrylamide Gel Electrophoresis, Capillary Gel Electrophoresis

4) By Mass Spectrometry: LC-MS/MS (Liquid Chromatography-Tandem Mass Spectrometry), MALDI-TOF MS (Matrix-Assisted Laser Desorption/Ionization Time of Flight), HRMS (High-Resolution Mass Spectrometry)

5) By Microarray: SNP Microarrays, Expression Microarrays, Comparative Genomic Hybridization (CGH) Arrays

6) By Other Technologies: Sanger Sequencing, CRISPR-Based Technologies, Bioinformatics Tools

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7072&type=smp

Who are the key players steering the development of the pharmacogenomics market?

Major companies operating in the pharmacogenomics market include Illumina Inc, Eurofins Scientific, Myriad Genetics Inc, PerkinElmer Inc, Centogene N.V, Invitae Corporation, Genomind, Pacific Biosciences of California Inc, Oneome LLC, Admera Health, MapMyGenome, Positive Bioscience, Xcode Life Sciences, Xcelris Labs, Takeda Pharmaceutical Company Limited, Garvan Institute of Medical Research, 3D Medicines Inc, Berry Genomics, BGI, GenomiCare Biotechnology, Bayer AG, GlaxoSmithKline plc (GSK), F Hoffmann-La Roche AG, Merck KGaA, QIAGEN N.V, Centro de Genoma e Biologia de Sistemas (CGBS), Dasa Group, Datar Cancer Genetics Limited, MedGenome Labs, 23andMe, Color Genomics, Pathway Genomics, Laboratório Richet, Laboratório Exame, Genomika Diagnósticos

What emerging trends are influencing the growth of the pharmacogenomics market?

The growth in technology is becoming a prevalent trend in the pharmacogenomics sector. Drug makers are increasingly turning to different strategies for pharmacogenomics evaluations to offer economical methods for detecting existing polymorphisms and identifying new variants. For instance, Invitae, a medical laboratory firm based in the US, unveiled its broader Pharmacogenomics Panel in May 2022. The Invitae PGx Panel, featuring the Mental Health Panel, offers insights into how genes react to medications across a range of fields such as primary care, cardiology, and oncology. As approximately 25% of patients exhibit unusual drug reactions due to their genetic makeup, PGx testing is on track to become routine procedure. However, for this to be effectively incorporated into healthcare, there needs to be increased support for care providers to comprehend and implement PGx testing in their clinical environments.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=7072

Which regions are most influential in expanding the pharmacogenomics market?

North America was the largest region in the pharmacogenomics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmacogenomics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Polymerase Chain Reactions (PCR) Devices, Reagents And Uses Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/polymerase-chain-reactions-devices-reagents-and-uses-global-market-report

Molecular Diagnostics Global Market Report 2022

https://www.thebusinessresearchcompany.com/report/molecular-diagnostics-global-market-report

Medical Equipment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/medical-equipment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How Will the Pharmacogenomics Market Grow Over the Forecast Period Based on Its Expected CAGR?

There has been a swift expansion in the market size of pharmacogenomics in the past few years. It is projected to balloon from the valuation of $8.94 billion in 2024 to reach approximately $9.92 billion in 2025, indicating a compound annual growth rate (CAGR) of 10.9%. Various elements have contributed to the observed growth in this historical timeframe, including significant economic advancements in emerging markets, a growing interest in personalized healthcare, evolving healthcare structures, and an upsurge in healthcare spending.

Expectations are high for the pharmacogenomics market to experience a significant upswing in the next few years. Analysts forecast a growth trajectory culminating in a value of $14.81 billion in 2029, representing a compound annual growth rate (CAGR) of 10.5%. The predicted increase throughout this period can be linked to factors such as the rise in the aging population, escalating chronic illnesses, burgeoning global populace and an increased demand in cancer treatment modalities. Peak trends for the forecast period involve the unveiling of genome editing solutions to enable more comprehensive analysis of sophisticated therapies, incorporation of artificial intelligence (AI) in genomics for genetic data scrutiny, emerging innovations in metagenomics, strategic alliances and collaborations within the market sphere, the advent of three-dimensional (3D) genomics to explore effects on gene expression and functionality, product breakthroughs concentrating on infectious diseases and gene editing, and the inception of psychotropic pharmacogenomics tests to facilitate informed decisions.

What Are the Primary Drivers Supporting the Growth of the pharmacogenomics Market?

The escalating need for precision medicine is fuelling the pharmacogenomics market’s growth. Precision medicine, a healthcare model that supports individualized care, suggests custom-made medical decisions, treatments, practices, or products for a specific patient group, deviating from a generic drug approach. Precision medicine, predominantly exceptional in oncology, exhibits promising potential in other areas like late-stage diseases and unique genetic diseases too. The primary goal of precision medicine is to amalgamate genetic and environmental information concerning specific diseases and their response to certain treatments. For instance, a Linchpinseo article posted in March 2022 indicates an anticipated 1/3 increase in precision medicine funding from leading pharmaceutical firms over the next five years. Additionally, in the USA, precision medicine is bringing about significant changes in the treatment of the 30 million type 2 diabetes patients, offering personalized care that will alter existing treatment protocols. Therefore, the growing need for precision medicine is projected to propel the pharmacogenomics market.

Explore Comprehensive Insights Into The Global Pharmacogenomics Market With A Free Sample Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7072&type=smp

Who Are the Dominant Players Expanding Their Reach in the Pharmacogenomics Market?

Major companies operating in the pharmacogenomics market include:

• Illumina Inc_x000D_

• Eurofins Scientific_x000D_

• Myriad Genetics Inc_x000D_

• PerkinElmer Inc_x000D_

• Centogene N.V_x000D_

What Are the Top Trends Shaping the Evolution of the Pharmacogenomics Market?

The uptick in the use of cutting-edge technology is a significant development witnessed in the pharmacogenomics market. Pharmaceutical manufacturers are emphasizing different methods of pharmacogenomics examination to offer cost-efficient results for known polymorphisms screening and new variants discovery. For instance, a medical laboratory company based in the United States, Invitae, introduced its enlarged Pharmacogenomics Panel in May 2022. This panel, otherwise known as the Pharmacogenomics (PGx) Panel, also includes the Mental Health Panel and provides genetic reactions to medications across various specialties such as primary care, cardiology, and oncology. Given that genetic factors cause unusual drug responses in nearly 25% of patients, PGx testing is on the road to becoming a standard procedure. For a seamless integration into healthcare, it’s essential to have strengthened backing for health providers to comprehend and utilize PGx testing in their healthcare practices.

Secure Your Global Pharmacogenomics Market Report Now for Fast and Efficient Delivery!

https://www.thebusinessresearchcompany.com/report/pharmacogenomics-global-market-report

What Are the Core Segments of the Pharmacogenomics Market, and How Do They Contribute to Growth?

The pharmacogenomics market covered in this report is segmented –

1) By Technology: Next Generation Sequencing, Polymerase Chain Reaction, Gel Electrophoresis, Mass Spectrometry, Microarray, Other Technologies

2) By Application: Neurological Diseases, Infectious Diseases, Oncology, Cardiovascular Diseases, Pain Management, Other Applications

3) By End User: Hospitals and Clinics, Research Institutions, Academic Institutes, Other End Users

Subsegments:

1) By Next Generation Sequencing (NGS): Whole Genome Sequencing, Targeted Sequencing, Exome Sequencing

2) By Polymerase Chain Reaction (PCR): Quantitative PCR (qPCR), Reverse Transcription PCR (RT-PCR), Digital PCR

3) By Gel Electrophoresis: Agarose Gel Electrophoresis, Polyacrylamide Gel Electrophoresis, Capillary Gel Electrophoresis

4) By Mass Spectrometry: LC-MS/MS (Liquid Chromatography-Tandem Mass Spectrometry), MALDI-TOF MS (Matrix-Assisted Laser Desorption/Ionization Time of Flight), HRMS (High-Resolution Mass Spectrometry)

5) By Microarray: SNP Microarrays, Expression Microarrays, Comparative Genomic Hybridization (CGH) Arrays

6) By Other Technologies: Sanger Sequencing, CRISPR-Based Technologies, Bioinformatics Tools

Which Regions Are Setting the Pace for Pharmacogenomics Market Growth?

North America was the largest region in the pharmacogenomics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmacogenomics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

How Is the Pharmacogenomics Market Defined Across Different Regions?

Pharmacogenomics is a field of research that studies how a patient’s genes affect and how they respond to medications. The long-term aim of pharmacogenomics is to help doctors select the drugs and doses best suited for each person. Pharmacogenomics is used to create customized drugs to treat a variety of health issues, including cardiovascular disease, Alzheimer’s disease, cancer, and asthma. The pharmacogenomics marker refers to precise medical treatment for each person or a group of people.

Browse Through More Similar Reports By The Business Research Company:

Polymerase Chain Reactions (PCR) Devices, Reagents And Uses Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/polymerase-chain-reactions-devices-reagents-and-uses-global-market-report

Molecular Diagnostics Global Market Report 2022

https://www.thebusinessresearchcompany.com/report/molecular-diagnostics-global-market-report

Medical Equipment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/medical-equipment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: